LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Effect of erythropoietin on cognitive side-effects of electroconvulsive therapy in depression: A randomized, double-blind, placebo-controlled trial.

Miskowiak, Kamilla W / Petersen, Jeff Z / Macoveanu, Julian / Ysbæk-Nielsen, Alexander T / Lindegaard, Ida A / Cramer, Katrine / Mogensen, Madel B / Hammershøj, Lisa G / Stougaard, Marie E / Jørgensen, Josefine L / Schmidt, Lejla Sjanic / Vinberg, Maj / Ehrenreich, Hannelore / Hageman, Ida / Videbech, Poul / Gbyl, Krzysztof / Kellner, Charles H / Kessing, Lars V / Jørgensen, Martin B

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

2023  Volume 79, Page(s) 38–48

Abstract: Electroconvulsive therapy (ECT) is one of the most effective and rapid-acting treatment for severe depression but is associated with cognitive side-effects. Identification of add-on treatments that counteract these side-effects would be very helpful. ... ...

Abstract Electroconvulsive therapy (ECT) is one of the most effective and rapid-acting treatment for severe depression but is associated with cognitive side-effects. Identification of add-on treatments that counteract these side-effects would be very helpful. This randomized, double-blinded, placebo-controlled, parallel-group study investigated the effects of four add-on erythropoietin (EPO; 40,000 IU/ml) or saline (placebo) infusions over 2.5 weeks of ECT (eight ECT sessions) in severely depressed patients with unipolar or bipolar depression. Neuropsychological assessments were conducted pre-ECT, three days after the eighth ECT (week 4), and at a 3-month follow-up. Further, functional magnetic resonance imaging (fMRI) was conducted after the eighth ECT. The primary outcome was change from pre- to post-ECT in a 'speed of complex cognitive processing' composite. Secondary outcomes were verbal and autobiographical memory. Of sixty randomized patients, one dropped out before baseline. Data were thus analysed for 59 patients (EPO, n = 33; saline, n = 26), of whom 28 had fMRI data. No ECT-related decline occurred in the primary global cognition measure (ps≥0.1), and no effect of EPO versus saline was observed on this outcome (ps≥0.3). However post-ECT, EPO-treated patients exhibited faster autobiographical memory recall than saline-treated patients (p = 0.02), which was accompanied by lower memory-related parietal cortex activity. The absence of global cognition changes with ECT and EPO, coupled with the specific impact of EPO on autobiographical memory recall speed and memory-related parietal cortex activity, suggests that assessing autobiographical memory may provide increased sensitivity in evaluating and potentially preventing cognitive side-effects of ECT. TRIAL REGISTRATIONS: ClinicalTrials.gov: NCT03339596, EudraCT no.: 2016-002326-36.
MeSH term(s) Humans ; Electroconvulsive Therapy/adverse effects ; Electroconvulsive Therapy/methods ; Depression ; Treatment Outcome ; Erythropoietin/therapeutic use ; Erythropoietin/pharmacology ; Epoetin Alfa ; Cognition ; Double-Blind Method
Chemical Substances Erythropoietin (11096-26-7) ; Epoetin Alfa (64FS3BFH5W)
Language English
Publishing date 2023-12-20
Publishing country Netherlands
Document type Randomized Controlled Trial ; Journal Article
ZDB-ID 1082947-7
ISSN 1873-7862 ; 0924-977X
ISSN (online) 1873-7862
ISSN 0924-977X
DOI 10.1016/j.euroneuro.2023.12.004
Shelf mark
Zs.A 3288: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)
Zs.MO 630: Show issues
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top